Lawyer profile for USA 2021
Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Intellectual Property: Patent Litigation - California
"She provides very thorough review and offers excellent advice. She is veryresponsive and able to translate sophisticated issues to a broad audience." "She has a strong knowledge of patent law and is organized and very responsive." "She is extremely bright, extremely personable and extremely efficient."
This content is provided by Cary Miller
Cary Miller, who holds a Ph.D. in cellular, developmental, and molecular biology, assists leading pharmaceutical, biotechnology and medical device companies to navigate complex patent issues—primarily for drug candidates and FDA approved products. Currently, Cary represents Celgene (now a Bristol Myers Squibb company) in multiple Hatch-Waxman litigations involving the top-selling pharmaceuticals Revlimid® and Pomalyst®. She has handled biosimilars litigation governed by the Biologics Price Competition and Innovation Act (BPCIA), and provides extensive counseling in that space. In the gene therapy sector, Cary represents plaintiff REGENXBIO in a patent lawsuit involving host cells for making DNA for gene therapy applications, and is defending REGENXBIO in a PGR challenging one of its gene therapy patents. She has successfully litigated patent cases through the U.S. and before the PTAB, Federal Circuit and Supreme Court. Cary leverages two decades of litigation experience to drive the development of cutting-edge patent portfolios with an eye towards thwarting litigation. Cary has significant experience involving patent term extension applications for drugs, biologics, and medical devices. She has drafted and prosecuted patents relating to breakthrough therapies in a number of areas, including antibodies and antibody-drug conjugates, cancer therapeutics and diagnostics, human embryonic stem cells, and drug delivery devices.